MGNX vs. XBIT, FHTX, ENTA, EBS, RANI, EPIX, ME, CRMD, ATAI, and PYXS
Should you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include XBiotech (XBIT), Foghorn Therapeutics (FHTX), Enanta Pharmaceuticals (ENTA), Emergent BioSolutions (EBS), Rani Therapeutics (RANI), ESSA Pharma (EPIX), 23andMe (ME), CorMedix (CRMD), Atai Life Sciences (ATAI), and Pyxis Oncology (PYXS). These companies are all part of the "pharmaceutical preparations" industry.
MacroGenics (NASDAQ:MGNX) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
In the previous week, MacroGenics had 11 more articles in the media than XBiotech. MarketBeat recorded 14 mentions for MacroGenics and 3 mentions for XBiotech. XBiotech's average media sentiment score of 0.63 beat MacroGenics' score of 0.14 indicating that XBiotech is being referred to more favorably in the news media.
MacroGenics presently has a consensus price target of $12.00, indicating a potential upside of 166.67%. Given MacroGenics' higher probable upside, equities research analysts plainly believe MacroGenics is more favorable than XBiotech.
XBiotech has a net margin of 0.00% compared to MacroGenics' net margin of -53.60%. XBiotech's return on equity of -13.98% beat MacroGenics' return on equity.
MacroGenics received 104 more outperform votes than XBiotech when rated by MarketBeat users. However, 69.98% of users gave XBiotech an outperform vote while only 63.12% of users gave MacroGenics an outperform vote.
96.9% of MacroGenics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 11.3% of MacroGenics shares are held by insiders. Comparatively, 33.1% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
MacroGenics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.
MacroGenics has higher revenue and earnings than XBiotech. MacroGenics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.
Summary
MacroGenics beats XBiotech on 9 of the 17 factors compared between the two stocks.
Get MacroGenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MacroGenics Competitors List
Related Companies and Tools
